-
Making investments to transform healthcare
Supporting breakthrough therapies and medical products that benefit patients and the healthcare system.
-
Funding novel, disruptive life science innovations
We provide capital and expertise to develop and market products with the potential to transform medical practice while building value for our investors.
-
-
„Sind Ideen immer Risiko?“ – Das neue Kapital
Wir fördern Zukunftsfinanzierung gemeinsam mit dem Bundesverband Beteiligungskapital e.V.
Our Approach
We have a unique two-pronged strategy. The first is the financing of innovative early-stage therapeutics through a single asset company approach that leverages our strategic relationship with global pharmaceutical firm Eli Lilly and Company. The second is to invest in differentiated commercial-stage medtech, diagnostics, and digital health products as well as late-stage therapeutics.
Our portfolio companies are a top priority.
>150
life science investments
900 M
Euro in Assets
Under Management
>100
Years of Venture Capital and Industry Expertise of Team Members